{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-012493","form_type":"8-K","ticker":"NRC","cik":"0000070487","company_name":"NRC HEALTH","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.967334+00:00","generated_at":"2026-06-15T23:30:00.592401+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"medium","headline":"National Research Q1 EPS falls to $0.28 from $0.34; capital allocation unchanged","bullets":["Diluted EPS $0.28 for Q1 2023, down from $0.34 in Q1 2022.","Company funded $2.9M for innovation and growth, $3.0M for dividends, $2.0M for share repurchases.","Board maintains capital allocation priorities: innovation, M&A, dividends, buybacks.","Announced MyView to integrate patient insights into EHR to support personalized care.","Expanding sales and marketing resources for Human Understanding Program."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-012493","json":"https://secwatch.observer/filing/0001437749-23-012493.json","markdown":"https://secwatch.observer/filing/0001437749-23-012493.md","text":"https://secwatch.observer/filing/0001437749-23-012493.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/70487/000143774923012493/0001437749-23-012493-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/70487/000143774923012493/nrc20230503_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T23:30:00.592401+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ecee4cdaf5d1991c6498ecf234a1da8b96372b1b","claim":"NRC HEALTH reported the first quarter ended March 31, 2023 results: EPS Diluted earnings per share decreased to $0.28 for the quarter ended March 31, 2023.","evidence_excerpt":"On May 2, 2023, National Research Corporation, a Delaware corporation (the \"Company\"), issued a press release announcing its financial and operating results for the first quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/70487/000143774923012493/0001437749-23-012493-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"EPS","value":"Diluted earnings per share decreased to $0.28 for the quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}